Past gains are not a representative of future gains. Co-Diagnostics is a client of BDA International. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. Parties interested in learning more about the relationship between BDA and CODX may do so via the contact information at the bottom of this release. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including CODX. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. The market certainly responded positively to the notion that Co-Diagnostics could be on the vanguard to providing a solution to a potential international emergency after jumping over 175% in pre-market trading, the stock price is currently trading up comfortably over 70%, on 30 million shares-a noticeable jump from the 116,000 average volume before releasing such momentous news!ĭisclosure: Co-Diagnostics Inc is a client of BDA International.īDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. That’s why Dwight Egan, Co-Diagnostics CEO, said that the company is working hard and has already completed initial design work on an accurate diagnostic test to detect the new strain of coronavirus, differentiating it from other similar viruses. The best way to confront this threat is through accurate diagnosis. With it taking up to a week for symptoms to start appearing, the world could potentially be on a brink of a global outbreak, with the World Health Organization on the cusp of calling it an global health emergency. In reality there are 6 types of coronavirus that can affect humans. There are a number of strains of coronavirus with hard to distinguish genetic differences, and a test designed for MERS and SARS – other coronaviruses, similar to the new strain, 2019n-CoV – would fail to accurately diagnose a patient with 2019nCoV. One of the fundamental problems that health authorities have at the moment is being able to properly diagnose and treat people. (Nasdaq: CODX), a biotech company with a patented platform for the development of molecular diagnostic tests, leaped 175+% in premarket trading today after announcing it is readying its screening test for the deadly, rapidly spreading new coronavirus.Īs governments across the world take precautions to limit exposure to the outbreak, especially China (who just announced the quarantine of a FIVE large cities to try and contain the coronavirus with more than 600 confirmed cases and at least 17 dead), Co-Diagnostics announced that it used its proprietary design platform to quickly design a PCR testing kit that will help in detecting the specific strain of virus in a patient. 23, 2020 (GLOBE NEWSWIRE) - Shares of Co-Diagnostics, Inc. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.New York City, Jan. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company also provides tests that identify genetic traits in plant and animal genomes and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |